Prostaglandins inhibit secretion of histamine and pancreastatin from isolated rat stomach ECL cells.
1. The present study examines the effect of naturally occurring prostanoids and prostaglandin (PG) congeners on gastrin- and pituitary adenylate cyclase-activating peptide (PACAP)-evoked histamine and pancreastatin secretion from isolated rat stomach ECL cells. 2. ECL cells (75-85% purity) were isolated from rat stomach using pronase digestion followed by repeated counter-flow elutriation and cultured for 48 h before secretion experiments. The release of histamine and pancreastatin was determined by radioimmunoassay. 3. None of the PGs tested stimulated the release of either histamine or pancreastatin. 4. PGE1 and PGE2 inhibited both gastrin- and PACAP-evoked histamine and pancreastatin secretion (IC50 = 1-2 x 10(-10) M). Most other naturally occuring prostanoids and PG congeners had no or little inhibitory effect. The PGE analogues misoprostol and sulprostone were more potent (IC50 = 0.9 x 10(-11) M and 2 x 10(-11) M respectively) than PGE1 and PGE2. The rank order of potency was misoprostol > sulprostone > PGE1 = PGE2, suggesting the involvement of the so-called EP3 receptor. 5. The effects of PGs on the stomach ECL cells may be direct or indirect, for instance through the stimulated release of somatostatin from contaminating D cells (2-3%). However, the amount of somatostatin in the cell culture after 48 h was below the limit of detection, and somatostatin immunoneutralization did not prevent misoprostol from inhibiting secretion from the ECL cells. 6. The misoprostol-induced inhibition was reversed by pertussis toxin suggesting the involvement of G-protein subunits G alpha(0) and/or G alpha(i). 7. In view of the potency by which PGE1, PGE2, misoprostol and sulprostone inhibited the stimulated release of histamine and pancreastatin, we suggest that the ECL cells represent a primary target for prostaglandins acting via an EP3 receptor in the oxyntic mucosa. 8. The results suggest that the clinically useful effect of misoprostol as an anti-ulcer drug reflects its ability to inhibit stomach ECL-cell histamine secretion.
Department of Pharmacology, University of Lund, Sweden.
E
E
Lindström
R
R
Håkanson
D000818:Animals; D002478:Cells, Cultured; D053379:Chromogranin A; D005753:Gastric Mucosa / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D005755:Gastrins / Q000494:pharmacology; D006636:Histamine Release / Q000187:drug effects*; D009479:Neuropeptides / Q000494:pharmacology; D010187:Pancreatic Hormones / Q000378:metabolism*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D011453:Prostaglandins / Q000494:pharmacology*; D051381:Rats
C495403:Adcyap1 protein, rat; D053379:Chromogranin A; D005755:Gastrins; D009479:Neuropeptides; D010187:Pancreatic Hormones; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D011453:Prostaglandins; C050836:pancreastatin